Table 5 Comparison of clinical features between patients who received CP transfusion on different time, with different doses, and with different NAb titers

From: The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series

 

Days from symptom onset to CP transfusion (n = 8)

Dose of CP transfusion (n = 7)

NAT50 of CP (n = 8)

≤21 day (n = 3)

>21 day (n = 5)

400 mL (n = 4)

200 mL (n = 3)

>1:640 (n = 3)

≤1:640 (n = 5)

Patient No.

Patient 2

Patient 3

Patient 7

Patient 1

Patient 4

Patient 5

Patient 6

Patient 8

Patient 1

Patient 2

Patient 3

Patient 5

Patient 6

Patient 7

Patient 8

Patient 4

Patient 5

Patient 7

Patient 1

Patient 2

Patient 3

Patient 6

Patient 8

Days from CP transfusion to Ct value ≥ 40

1.00a

5.00 (2.00–7.00)

1.00a

5.00b

2.00b

3.00 (1.00–7.00)

virus-specific IgG titer ratio

1.20 (1.15–1.85)

1.06 (0.99–1.54)

1.15 (1.10–1.21)

1.69 (0.97–1.85)

1.44b

1.15 (1.00–1.45)

Length of hospital stay, days

20.00 (18.00–28.00)

32.50 (28.50–35.75)

27.50 (18.50–35.75)

28.00 (28.00–30.00)

31.50b

24.00 (19.00–33.00)

  1. Data are indicated as median (IQR). The virus-specific IgG titer ratio indicates the value tested by MCLIA at day 1 after CP transfusion divided by the value before CP transfusion
  2. CP convalescent plasma, NAT50 neutralizing antibody titer which was calculated with the highest dilution of plasma that resulted in a 50% reduction of virus infection
  3. aDays from CP transfusion to Ct value≥40 for all eligible patients was 1.00 day
  4. bData represented the individual or average value due to lack of clinical source
Back to article page